| 000 | 01888 a2200553 4500 | ||
|---|---|---|---|
| 005 | 20250516104508.0 | ||
| 264 | 0 | _c20130219 | |
| 008 | 201302s 0 0 eng d | ||
| 022 | _a1932-6203 | ||
| 024 | 7 |
_a10.1371/journal.pone.0042863 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aHaaß, Wiltrud | |
| 245 | 0 | 0 |
_aThe proteolytic activity of separase in BCR-ABL-positive cells is increased by imatinib. _h[electronic resource] |
| 260 |
_bPloS one _c2012 |
||
| 300 |
_ae42863 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAntineoplastic Agents _xpharmacology |
| 650 | 0 | 4 | _aBenzamides |
| 650 | 0 | 4 |
_aBlast Crisis _xdrug therapy |
| 650 | 0 | 4 |
_aCell Cycle Proteins _xgenetics |
| 650 | 0 | 4 |
_aCyclin B1 _xgenetics |
| 650 | 0 | 4 |
_aDrug Resistance, Neoplasm _xdrug effects |
| 650 | 0 | 4 |
_aEndopeptidases _xgenetics |
| 650 | 0 | 4 |
_aFusion Proteins, bcr-abl _xgenetics |
| 650 | 0 | 4 |
_aGenomic Instability _xdrug effects |
| 650 | 0 | 4 | _aHL-60 Cells |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aImatinib Mesylate |
| 650 | 0 | 4 | _aK562 Cells |
| 650 | 0 | 4 |
_aLeukemia, Myelogenous, Chronic, BCR-ABL Positive _xdrug therapy |
| 650 | 0 | 4 |
_aNeoplasm Proteins _xgenetics |
| 650 | 0 | 4 |
_aPhosphorylation _xdrug effects |
| 650 | 0 | 4 |
_aPiperazines _xpharmacology |
| 650 | 0 | 4 |
_aProtein Phosphatase 2 _xgenetics |
| 650 | 0 | 4 | _aProteolysis |
| 650 | 0 | 4 |
_aPyrimidines _xpharmacology |
| 650 | 0 | 4 | _aSecurin |
| 650 | 0 | 4 | _aSeparase |
| 650 | 0 | 4 | _aU937 Cells |
| 700 | 1 | _aStehle, Michael | |
| 700 | 1 | _aNittka, Stefanie | |
| 700 | 1 | _aGiehl, Michelle | |
| 700 | 1 | _aSchrotz-King, Petra | |
| 700 | 1 | _aFabarius, Alice | |
| 700 | 1 | _aHofmann, Wolf-Karsten | |
| 700 | 1 | _aSeifarth, Wolfgang | |
| 773 | 0 |
_tPloS one _gvol. 7 _gno. 8 _gp. e42863 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1371/journal.pone.0042863 _zAvailable from publisher's website |
| 999 |
_c22005429 _d22005429 |
||